WALTHAM, Mass., April 21, 2016 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced it has signed an agreement with Reimbursement Specialists, Inc., a Comprehensive Benefit Administrators (CBA) company and leading provider of benefits management services, to include coverage for Interleukin’s PerioPredict® Genetic Risk Test as part of CBA’s Freedom Dental Plan.
PerioPredict identifies individuals at increased risk for severe periodontitis due to a genetic tendency to over-produce chronic inflammation, an underlying root cause of many chronic diseases. The test delivers genetic information that can improve risk stratification and support increased preventative dental care, which in turn can significantly lower a patient’s systemic inflammatory burden and potentially reduce the risk of periodontitis and other chronic diseases.
PerioPredict testing through CBA’s Freedom Dental Plan will guide additional preventative care for patients with increased risk for developing severe periodontal disease as identified by a positive test result.
“We are thrilled to add an innovative new benefit that uses genetic testing to drive personalized care as a component to our Freedom Dental Plan,” said Mike McKenna, President and Chief Executive Officer of CBA. “This unique test will differentiate our plan, providing added value for current and prospective customers.”
“CBA is a perfect partner to extend PerioPredict in the New England market. Their team recognized early on the importance of integrating medical and dental sciences in a more holistic approach to health to improve wellness and ultimately reduce long-term healthcare costs,” said Mark Carbeau, Chief Executive Officer of Interleukin Genetics. “Adding PerioPredict as a covered benefit in CBA’s Freedom Dental Plan is yet another strong step forward for Interleukin as we continue to gain traction in the marketplace for our innovative testing and patient engagement program. We are delighted to work with CBA to expand access to our PerioPredict test.”
Periodontal disease is one of the most common chronic inflammatory diseases in developed countries, and studies document that better control of the condition has been shown to significantly lower the systemic inflammatory burden. Studies also demonstrate that proper management of periodontitis substantially lowers medical costs for patients with certain chronic diseases.
PerioPredict is an innovative, easy-to-use genetic test that identifies individuals with an increased risk for severe and progressive periodontitis, due to a life-long genetic predisposition to over-produce Interleukin-1 (IL-1), a key mediator of inflammation. Such individuals may benefit from enhanced dental care to prevent or treat periodontitis and thereby lower their systemic inflammatory burden. Targeted management of systemic inflammation has been shown to help manage several chronic diseases, including type 2 diabetes and coronary artery disease. The PerioPredict test is made available to employees in covered health plans under the supervision of a licensed dentist or physician, and the results provide important information to dental professionals for assessing prevention and treatment options for their patients. The PerioPredict test is run solely in Interleukin’s CLIA-certified lab in Waltham, MA. For more information, please visit www.PerioPredict.com.
About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions, and for informing lifestyle choices to facilitate wellness. Our tests provide information that is not otherwise available to empower individuals and their healthcare providers to manage their health and wellness through genetics-based insights and actionable guidance. Interleukin Genetics leverages its research, intellectual property, and genetic panel development expertise in inflammation and metabolism to identify individuals whose risk for certain chronic disease may be increased due to variants in one or more genes, which can enable a more targeted approach to the individual’s healthcare. The company markets its tests through healthcare professionals, partnerships with health and wellness companies, and other distribution channels. Interleukin Genetics’ lead products include its proprietary PerioPredict® genetic test that identifies individuals at risk for severe periodontal disease and a life-long predisposition to overproduce inflammation, and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com.
About Comprehensive Benefit Administrators
Comprehensive Benefit Administrators, previously known as Partners Benefit Group, was founded by Michael McKenna. Under his direction, the firm changed its name to Comprehensive Benefit Administrators to more accurately reflect the wider scope of services that the company offers. Comprehensive Benefit Administrators (CBA) combines traditional brokerage services with specialty services such as advocacy, claims administration, benefits expertise, and compliance, to provide customers with extensive capabilities through one source. Offering a wide range of resources, Partners Benefit Group division, specializing in medical, dental, life, disability and group health insurance; their Reimbursement Specialists, Inc. division, a third-party claims administrator advising companies on how to save on their healthcare costs through creative healthcare funding options; and ComplianceSource, a division which advises and assists companies in becoming compliant with federal regulations. To learn more about the company, visit www.cbacompanies.com or call (877) 993-5600.
Certain statements contained herein are “forward-looking” statements. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in Interleukin’s annual report on Form 10-K for the year ended December 31, 2015, and other filings with the Securities and Exchange Commission. Interleukin disclaims any obligation or intention to update these forward-looking statements.
Source:Interleukin Genetics, Inc.